Ausgabe 1/2000
Inhalt (16 Artikel)
Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?
Lee Green
Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!
Peter Sleight
Debate: A subversive view of subsets - a dissident clinician's opinion
Desmond G Julian
Clinical trials in developing countries: Discussions at the “9th International Symposium on Long Term Clinical Trials”, London, UK, 19-20 June 2000
Rachel N Johnatty
Current Controlled Trials: an opportunity to help improve the quality of clinical research
Iain Chalmers
Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?
Hans-Peter Vosberg
Debate: When should we intervene in unstable angina - Time for an old look?
Warren K Laskey
Importance of the TIMI frame count: implications for future trials
Mark A Appleby, Andrew D Michaels, Michael Chen, C Gibson Michael
Medical errors: how the US Government is addressing the problem
Kevin A Schulman, John J Kim
Long-term outcome after coronary stenting
Adnan Kastrati, Donald Hall, Albert Schömig
Why do antioxidants fail to provide clinical benefit?
Ascan Warnholtz, Thomas Münzel
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial
Pierre Theroux, Bernard R Chaitman, Leif Erhardt, Andreas Jessel, Thomas Meinertz, Wolf-Ulrich Nickel, John S Schroeder, Gianni Tognoni, Harvey White, James T Willerson
Use of intravenous antiarrhythmics to identify concealed Brugada syndrome
Ramon Brugada
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)
Curt Furberg, Bertram Pitt